187 related articles for article (PubMed ID: 32621252)
1. Dynamic contrast-enhanced magnetic resonance imaging for risk-stratified screening in women with BRCA mutations or high familial risk for breast cancer: are we there yet?
Whitaker KD; Sheth D; Olopade OI
Breast Cancer Res Treat; 2020 Sep; 183(2):243-250. PubMed ID: 32621252
[TBL] [Abstract][Full Text] [Related]
2. Should women with a BRCA1/2 mutation aged 60 and older be offered intensified breast cancer screening? - A cost-effectiveness analysis.
Phi XA; Greuter MJW; Obdeijn IM; Oosterwijk JC; Feenstra TL; Houssami N; de Bock GH
Breast; 2019 Jun; 45():82-88. PubMed ID: 30904701
[TBL] [Abstract][Full Text] [Related]
3. Triple-modality screening trial for familial breast cancer underlines the importance of magnetic resonance imaging and questions the role of mammography and ultrasound regardless of patient mutation status, age, and breast density.
Riedl CC; Luft N; Bernhart C; Weber M; Bernathova M; Tea MK; Rudas M; Singer CF; Helbich TH
J Clin Oncol; 2015 Apr; 33(10):1128-35. PubMed ID: 25713430
[TBL] [Abstract][Full Text] [Related]
4. Magnetic resonance imaging improves breast screening sensitivity in BRCA mutation carriers age ≥ 50 years: evidence from an individual patient data meta-analysis.
Phi XA; Houssami N; Obdeijn IM; Warner E; Sardanelli F; Leach MO; Riedl CC; Trop I; Tilanus-Linthorst MM; Mandel R; Santoro F; Kwan-Lim G; Helbich TH; de Koning HJ; Van den Heuvel ER; de Bock GH
J Clin Oncol; 2015 Feb; 33(4):349-56. PubMed ID: 25534390
[TBL] [Abstract][Full Text] [Related]
5. Intensive Surveillance with Biannual Dynamic Contrast-Enhanced Magnetic Resonance Imaging Downstages Breast Cancer in
Guindalini RSC; Zheng Y; Abe H; Whitaker K; Yoshimatsu TF; Walsh T; Schacht D; Kulkarni K; Sheth D; Verp MS; Bradbury AR; Churpek J; Obeid E; Mueller J; Khramtsova G; Liu F; Raoul A; Cao H; Romero IL; Hong S; Livingston R; Jaskowiak N; Wang X; Debiasi M; Pritchard CC; King MC; Karczmar G; Newstead GM; Huo D; Olopade OI
Clin Cancer Res; 2019 Mar; 25(6):1786-1794. PubMed ID: 30154229
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of screening with contrast enhanced magnetic resonance imaging vs X-ray mammography of women at a high familial risk of breast cancer.
Griebsch I; Brown J; Boggis C; Dixon A; Dixon M; Easton D; Eeles R; Evans DG; Gilbert FJ; Hawnaur J; Kessar P; Lakhani SR; Moss SM; Nerurkar A; Padhani AR; Pointon LJ; Potterton J; Thompson D; Turnbull LW; Walker LG; Warren R; Leach MO;
Br J Cancer; 2006 Oct; 95(7):801-10. PubMed ID: 17016484
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of Breast Cancer Screening With Magnetic Resonance Imaging for Women at Familial Risk.
Geuzinge HA; Obdeijn IM; Rutgers EJT; Saadatmand S; Mann RM; Oosterwijk JC; Tollenaar RAEM; de Roy van Zuidewijn DBW; Lobbes MBI; van 't Riet M; Hooning MJ; Ausems MGEM; Loo CE; Wesseling J; Luiten EJT; Zonderland HM; Verhoef C; Heijnsdijk EAM; Tilanus-Linthorst MMA; de Koning HJ;
JAMA Oncol; 2020 Sep; 6(9):1381-1389. PubMed ID: 32729887
[TBL] [Abstract][Full Text] [Related]
8. The added value of mammography in different age-groups of women with and without BRCA mutation screened with breast MRI.
Vreemann S; van Zelst JCM; Schlooz-Vries M; Bult P; Hoogerbrugge N; Karssemeijer N; Gubern-Mérida A; Mann RM
Breast Cancer Res; 2018 Aug; 20(1):84. PubMed ID: 30075794
[TBL] [Abstract][Full Text] [Related]
9. Five screening-detected breast cancer cases in initially disease-free BRCA1 or BRCA2 mutation carriers.
Shimada S; Yoshida R; Nakashima E; Kitagawa D; Gomi N; Horii R; Takeuchi S; Ashihara Y; Kita M; Akiyama F; Ohno S; Saito M; Arai M
Breast Cancer; 2019 Nov; 26(6):846-851. PubMed ID: 30980249
[TBL] [Abstract][Full Text] [Related]
10. Pregnancy Associated Breast Cancer Among Israeli BRCA1/BRCA2 Carriers in a High-Risk Clinic.
Faermann R; Friedman E; Kaidar-Person O; Brodsky M; Neiman OH; Shalmon A; Gotlieb M; Yagil Y; Samocha D; Feldman DM; Weidenfeld J; Sklair-Levy M
Acad Radiol; 2023 Feb; 30(2):248-254. PubMed ID: 35527100
[TBL] [Abstract][Full Text] [Related]
11. Cancer screening with digital mammography for women at average risk for breast cancer, magnetic resonance imaging (MRI) for women at high risk: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(3):1-55. PubMed ID: 23074406
[TBL] [Abstract][Full Text] [Related]
12. MRI versus mammography for breast cancer screening in women with familial risk (FaMRIsc): a multicentre, randomised, controlled trial.
Saadatmand S; Geuzinge HA; Rutgers EJT; Mann RM; de Roy van Zuidewijn DBW; Zonderland HM; Tollenaar RAEM; Lobbes MBI; Ausems MGEM; van 't Riet M; Hooning MJ; Mares-Engelberts I; Luiten EJT; Heijnsdijk EAM; Verhoef C; Karssemeijer N; Oosterwijk JC; Obdeijn IM; de Koning HJ; Tilanus-Linthorst MMA;
Lancet Oncol; 2019 Aug; 20(8):1136-1147. PubMed ID: 31221620
[TBL] [Abstract][Full Text] [Related]
13. Breast cancer detection and tumor characteristics in BRCA1 and BRCA2 mutation carriers.
Krammer J; Pinker-Domenig K; Robson ME; Gönen M; Bernard-Davila B; Morris EA; Mangino DA; Jochelson MS
Breast Cancer Res Treat; 2017 Jun; 163(3):565-571. PubMed ID: 28343309
[TBL] [Abstract][Full Text] [Related]
14. Surveillance of Women with the BRCA1 or BRCA2 Mutation by Using Biannual Automated Breast US, MR Imaging, and Mammography.
van Zelst JCM; Mus RDM; Woldringh G; Rutten MJCM; Bult P; Vreemann S; de Jong M; Karssemeijer N; Hoogerbrugge N; Mann RM
Radiology; 2017 Nov; 285(2):376-388. PubMed ID: 28609204
[TBL] [Abstract][Full Text] [Related]
15. MRI breast screening in high-risk women: cancer detection and survival analysis.
Evans DG; Kesavan N; Lim Y; Gadde S; Hurley E; Massat NJ; Maxwell AJ; Ingham S; Eeles R; Leach MO; ; Howell A; Duffy SW
Breast Cancer Res Treat; 2014 Jun; 145(3):663-72. PubMed ID: 24687378
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of alternating magnetic resonance imaging and digital mammography screening in BRCA1 and BRCA2 gene mutation carriers.
Cott Chubiz JE; Lee JM; Gilmore ME; Kong CY; Lowry KP; Halpern EF; McMahon PM; Ryan PD; Gazelle GS
Cancer; 2013 Mar; 119(6):1266-76. PubMed ID: 23184400
[TBL] [Abstract][Full Text] [Related]
17. Screening of women at high risk for breast cancer.
Narod SA
Prev Med; 2011 Sep; 53(3):127-30. PubMed ID: 21745498
[TBL] [Abstract][Full Text] [Related]
18. The supplemental value of mammographic screening over breast MRI alone in BRCA2 mutation carriers.
Obdeijn IM; Mann RM; Loo CCE; Lobbes M; Voormolen EMC; van Deurzen CHM; de Bock G; ; Hooning MJ
Breast Cancer Res Treat; 2020 Jun; 181(3):581-588. PubMed ID: 32333294
[TBL] [Abstract][Full Text] [Related]
19. BRCA1/BRCA2 mutations in Japanese women with ductal carcinoma in situ.
Liu Y; Ide Y; Inuzuka M; Tazawa S; Kanada Y; Matsunaga Y; Kuwayama T; Sawada T; Akashi-Tanaka S; Nakamura S
Mol Genet Genomic Med; 2019 Mar; 7(3):e493. PubMed ID: 30652428
[TBL] [Abstract][Full Text] [Related]
20. Cancers in BRCA1 and BRCA2 carriers and in women at high risk for breast cancer: MR imaging and mammographic features.
Gilbert FJ; Warren RM; Kwan-Lim G; Thompson DJ; Eeles RA; Evans DG; Leach MO;
Radiology; 2009 Aug; 252(2):358-68. PubMed ID: 19703879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
